Related references
Note: Only part of the references are listed.Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusion-Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II Study
David P. Steensma et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Lenalidomide-Epoetin Alfa Versus Lenalidomide Monotherapy in Myelodysplastic Syndromes Refractory to Recombinant Erythropoietin
Alan F. List et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Validation of International Working Group response criteria in higher-risk myelodysplastic syndromes: A report on behalf of the MDS Clinical Research Consortium
Rami S. Komrokji et al.
CANCER MEDICINE (2021)
Treatment options for lower-risk myelodysplastic syndromes. Where are we now?
Virginia O. Volpe et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2021)
Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes
Anthony M. Hunter et al.
BLOOD ADVANCES (2021)
Use of immunosuppressive therapy for management of myelodysplastic syndromes: a systematic review and meta-analysis
Maximilian Stahl et al.
HAEMATOLOGICA (2020)
Association of provider experience and clinical outcomes in patients with myelodysplastic syndromes receiving hypomethylating agents
Amer M. Zeidan et al.
LEUKEMIA & LYMPHOMA (2020)
Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes
Pierre Fenaux et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Comparison of Patient Age Groups in Transplantation for Myelodysplastic Syndrome The Medicare Coverage With Evidence Development Study
Ehab Atallah et al.
JAMA ONCOLOGY (2020)
Therapeutic Targeting of the Macrophage Immune Checkpoint CD47 in Myeloid Malignancies
Mark P. Chao et al.
FRONTIERS IN ONCOLOGY (2020)
Iron Chelation in Transfusion-Dependent Patients With Low- to Intermediate-1-Risk Myelodysplastic Syndromes A Randomized Trial
Emanuele Angelucci et al.
ANNALS OF INTERNAL MEDICINE (2020)
SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS
Luca Malcovati et al.
BLOOD (2020)
Phase II study of pevonedistat (P) + azacitidine (A) versus A in patients (pts) with higher-risk myelodysplastic syndromes (MDS)/chronic myelomonocytic leukemia (CMML), or low-blast acute myelogenous leukemia (LB AML) (NCT02610777).
Lionel Ades et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
A phase III study of venetoclax plus low-dose cytarabine in previously untreated older patients with acute myeloid leukemia (VIALE-C): A six-month update.
Andrew H. Wei et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
To target the untargetable: elucidation of synergy of APR-246 and azacitidine in TP53 mutant myelodysplastic syndromes and acute myeloid leukemia
David A. Sallman
HAEMATOLOGICA (2020)
Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure
Brian J. Ball et al.
BLOOD ADVANCES (2020)
Comparison of induction strategies and responses for acute myeloid leukemia patients after resistance to hypomethylating agents for antecedent myeloid malignancy
Chetasi Talati et al.
LEUKEMIA RESEARCH (2020)
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
C. D. DiNardo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients with Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS): Updated Results from a Phase 1b Study
Andrew M. Brunner et al.
BLOOD (2020)
Phase 3 Study of Lenalidomide (LEN) Vs Placebo in Non-Transfusion Dependent (TD) Low Risk Del(5q) MDS Patients - Interim Analysis of the European Sintra-REV Trial
Felix Lopez Cadenas et al.
BLOOD (2020)
A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients
Betul Oran et al.
BLOOD ADVANCES (2020)
Transforming growth factor (TGF)-β pathway as a therapeutic target in lower risk myelodysplastic syndromes
Jan Philipp Bewersdorf et al.
LEUKEMIA (2019)
Activin Receptor II Ligand Traps: New Treatment Paradigm for Low-Risk MDS
Rami S. Komrokji
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2019)
Ivosidenib (AG-120) in Patients with IDH1-Mutant Relapsed/Refractory Myelodysplastic Syndrome: Updated Enrollment of a Phase 1 Dose Escalation and Expansion Study
James M. Foran et al.
BLOOD (2019)
The First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Azacitidine Is Effective in MDS and AML Patients: Ongoing Phase 1b Results
David A. Sallman et al.
BLOOD (2019)
Pharmacokinetic Exposure Equivalence and Preliminary Efficacy and Safety from a Randomized Cross over Phase 3 Study (ASCERTAIN study) of an Oral Hypomethylating Agent ASTX727 (cedazuridine/decitabine) Compared to IV Decitabine
Guillermo Garcia-Manero et al.
BLOOD (2019)
A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax As Monotherapy or in Combination with Azacitidine for the Treatment of Relapsed/Refractory Myelodysplastic Syndrome
Amer M. Zeidan et al.
BLOOD (2019)
NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy
Guillermo Montalban-Bravo et al.
BLOOD ADVANCES (2019)
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
C. D. DiNardo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
APR-246 reactivates mutant p53 by targeting cysteines 124 and 277
Qiang Zhang et al.
CELL DEATH & DISEASE (2018)
Efficacy of azacitidine is independent of molecular and clinical characteristics-an analysis of 128 patients with myelodysplastic syndromes or acute myeloid leukemia and a review of the literature
Andrea Kuendgen et al.
Oncotarget (2018)
Prognosis of patients with intermediate risk IPSS-R myelodysplastic syndrome indicates variable outcomes and need for models beyond IPSS-R
Christopher B. Benton et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Phase 1b study of venetoclax in combination with azacitidine in patients with treatment-naive higher-risk myelodysplastic syndromes.
Chun Yew Fong et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort
Maximilian Stahl et al.
BLOOD ADVANCES (2018)
Isocitrate dehydrogenase mutations in myeloid malignancies
B. C. Medeiros et al.
LEUKEMIA (2017)
Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study
Nancy K. Gillis et al.
LANCET ONCOLOGY (2017)
A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes
U. Platzbecker et al.
LEUKEMIA (2017)
Relation between chelation and clinical outcomes in lower-risk patients with patients with myelodysplastic syndromes: Registry analysis at 5 years
Roger M. Lyons et al.
LEUKEMIA RESEARCH (2017)
ASXL1 frameshift mutations drive inferior outcomes in CMML without negative impact in MDS
David A. Sallman et al.
BLOOD CANCER JOURNAL (2017)
Functional expression of Tim-3 on blasts and clinical impact of its ligand galectin-9 in myelodysplastic syndromes
Toshio Asayama et al.
ONCOTARGET (2017)
Molecular Data and the IPSS-R: How Mutational Burden Can Affect Prognostication in MDS
Aziz Nazha et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2017)
Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial
Esther N. Oliva et al.
LANCET HAEMATOLOGY (2017)
PRIMA-1 and PRIMA-1Met (APR-246): From Mutant/Wild Type p53 Reactivation to Unexpected Mechanisms Underlying Their Potent Anti-Tumor Effect in Combinatorial Therapies
Anne Perdrix et al.
CANCERS (2017)
A Call for Action: Increasing Enrollment of Untreated Patients With Higher-Risk Myelodysplastic Syndromes in First-Line Clinical Trials
Amer M. Zeidan et al.
CANCER (2017)
Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN
Elias Jabbour et al.
BLOOD (2017)
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
Eytan M. Stein et al.
BLOOD (2017)
Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel
Theo de Witte et al.
BLOOD (2017)
Allogeneic Stem Cell Transplantation for Patients Age ≥ 70 Years with Myelodysplastic Syndrome: A Retrospective Study of the MDS Subcommittee of the Chronic Malignancies Working Party of the EBMT
Silke Heidenreich et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2017)
Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides
A. M. Zeidan et al.
LEUKEMIA (2016)
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Daniel A. Arber et al.
BLOOD (2016)
Patient-related factors independently impact overall survival in patients with myelodysplastic syndromes: an MDS-CAN prospective study
Rena Buckstein et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
Mutational correlates of response to hypomethylating agent therapy in acute myeloid leukemia
Catherine C. Coombs et al.
HAEMATOLOGICA (2016)
Are somatic mutations predictive of response to erythropoiesis stimulating agents in lower risk myelodysplastic syndromes?
Olivier Kosmider et al.
HAEMATOLOGICA (2016)
A randomized phase II trial of azacitidine plus /- epoetin-β in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents
Sylvain Thepot et al.
HAEMATOLOGICA (2016)
Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents
Valeria Santini et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes
J. S. Welch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Genomic Classification and Prognosis in Acute Myeloid Leukemia
Elli Papaemmanuil et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
An open-label phase I dose-finding study of APR-246 in hematological malignancies
S. Deneberg et al.
BLOOD CANCER JOURNAL (2016)
Mutations in histone modulators are associated with prolonged survival during azacitidine therapy
Magnus Tobiasson et al.
ONCOTARGET (2016)
Mutational correlates of response to hypomethylating agent therapy in acute myeloid leukemia
Catherine C. Coombs et al.
HAEMATOLOGICA (2016)
Are somatic mutations predictive of response to erythropoiesis stimulating agents in lower risk myelodysplastic syndromes?
Olivier Kosmider et al.
HAEMATOLOGICA (2016)
A randomized phase II trial of azacitidine plus /- epoetin-β in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents
Sylvain Thepot et al.
HAEMATOLOGICA (2016)
Enasidenib (AG-221), a Potent Oral Inhibitor of Mutant Isocitrate Dehydrogenase 2 (IDH2) Enzyme, Induces Hematologic Responses in Patients with Myelodysplastic Syndromes (MDS)
Eytan M. Stein et al.
BLOOD (2016)
Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes
David P. Steensma et al.
BLOOD (2015)
Treatment strategies in patients with AML or high-risk myelodysplastic syndrome relapsed after Allo-SCT
T. Sauer et al.
BONE MARROW TRANSPLANTATION (2015)
Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study
Ronan T. Swords et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Lenalidomide Treatment for Lower Risk Nondeletion 5q Myelodysplastic Syndromes Patients Yields Higher Response Rates When Used Before Azacitidine
Amer M. Zeidan et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2015)
Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registry
T. Bernal et al.
LEUKEMIA (2015)
A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis
Ayalew Tefferi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia
Gabriela M. Baerlocher et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential
Jie Liu et al.
PLOS ONE (2015)
Standards and Impact of Hematopathology in Myelodysplastic Syndromes (MDS)
Oncotarget (2015)
Familial myelodysplastic syndrome/acute leukemia syndromes: a review and utility for translational investigations
Allison H. West et al.
BONE MARROW NICHE, STEM CELLS, AND LEUKEMIA: IMPACT OF DRUGS, CHEMICALS, AND THE ENVIRONMENT (2014)
TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients
Rafael Bejar et al.
BLOOD (2014)
Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R
Matteo G. Della Porta et al.
BLOOD (2014)
Telomerase Inhibition Effectively Targets Mouse and Human AML Stem Cells and Delays Relapse following Chemotherapy
Claudia Bruedigam et al.
CELL STEM CELL (2014)
Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial)
Emanuele Angelucci et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2014)
Somatic Mutations Predict Poor Outcome in Patients With Myelodysplastic Syndrome After Hematopoietic Stem-Cell Transplantation
Rafael Bejar et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Adequate iron chelation therapy for at least six months improves survival in transfusion-dependent patients with lower risk myelodysplastic syndromes
Michel Delforge et al.
LEUKEMIA RESEARCH (2014)
Clonal Hematopoiesis and Blood-Cancer Risk Inferred from Blood DNA Sequence
Giulio Genovese et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes
Siddhartha Jaiswal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Telomerase Inhibitor Imetelstat (GRN163L) Limits the Lifespan of Human Pancreatic Cancer Cells
Katrina M. Burchett et al.
PLOS ONE (2014)
Limited clinical efficacy of azacitidine in transfusion-dependent, growth factor-resistant, low- and Int-1-risk MDS: Results from the nordic NMDSG08A phase II trial
M. Tobiasson et al.
BLOOD CANCER JOURNAL (2014)
Efficacy and Safety of Lenalidomide (LEN) Versus Placebo (PBO) in RBC-Transfusion Dependent (TD) Patients (Pts) with IPSS Low/Intermediate (Int-1)-Risk Myelodysplastic Syndromes (MDS) without Del(5q) and Unresponsive or Refractory to Erythropoiesis-Stimulating Agents (ESAs): Results from a Randomized Phase 3 Study (CC-5013-MDS-005)
Valeria Santini et al.
BLOOD (2014)
Clinical and biological implications of driver mutations in myelodysplastic syndromes
Elli Papaemmanuil et al.
BLOOD (2013)
BCL-2 Inhibition Targets Oxidative Phosphorylation and Selectively Eradicates Quiescent Human Leukemia Stem Cells
Eleni D. Lagadinou et al.
CELL STEM CELL (2013)
Prognostic Factors and Risk Models in Myelodysplastic Syndromes
Rami S. Komrokji et al.
Clinical Lymphoma Myeloma & Leukemia (2013)
Induction of myelodysplasia by myeloid-derived suppressor cells
Xianghong Chen et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Revised International Prognostic Scoring System (IPSS) Predicts Survival and Leukemic Evolution of Myelodysplastic Syndromes Significantly Better Than IPSS and WHO Prognostic Scoring System: Validation by the Gruppo Romano Mielodisplasie Italian Regional Database
Maria Teresa Voso et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Toll-like receptor alterations in myelodysplastic syndrome
Y. Wei et al.
LEUKEMIA (2013)
Overexpression of the Toll-Like Receptor (TLR) Signaling Adaptor MYD88, but Lack of Genetic Mutation, in Myelodysplastic Syndromes
Sophie Dimicoli et al.
PLOS ONE (2013)
Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes
Wendy W. Pang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Characteristics and Outcome Of Myelodysplastic Syndromes (MDS) Patients With Autoimmune Diseases
Rami S. Komrokji et al.
BLOOD (2013)
Pretransplantation Therapy with Azacitidine vs Induction Chemotherapy and Posttransplantation Outcome in Patients with MDS
Aaron T. Gerds et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2012)
SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML)
Manja Meggendorfer et al.
BLOOD (2012)
Combined treatment with lenalidomide and epoetin alfa in lower-risk patients with myelodysplastic syndrome
Rami S. Komrokji et al.
BLOOD (2012)
Revised International Prognostic Scoring System for Myelodysplastic Syndromes
Peter L. Greenberg et al.
BLOOD (2012)
The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications
Mark P. Chao et al.
CURRENT OPINION IN IMMUNOLOGY (2012)
Impact of Azacitidine Before Allogeneic Stem-Cell Transplantation for Myelodysplastic Syndromes: A Study by the Societe Francaise de Greffe de Moelle et de Therapie-Cellulaire and the Groupe-Francophone des Myelodysplasies
Gandhi Damaj et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Targeting p53 in Vivo: A First-in-Human Study With p53-Targeting Compound APR-246 in Refractory Hematologic Malignancies and Prostate Cancer
Soren Lehmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Expansion of Effector Memory Regulatory T Cells Represents a Novel Prognostic Factor in Lower Risk Myelodysplastic Syndrome
Adam W. Mailloux et al.
JOURNAL OF IMMUNOLOGY (2012)
DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia
K. H. Metzeler et al.
LEUKEMIA (2012)
Molecular genetics in myelodysplastic syndromes
Torsten Haferlach
LEUKEMIA RESEARCH (2012)
Clonal Architecture of Secondary Acute Myeloid Leukemia
Matthew J. Walter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Dysplasia Has A Differential Diagnosis: Distinguishing Genuine Myelodysplastic Syndromes (MDS) From Mimics, Imitators, Copycats and Impostors
David P. Steensma
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2012)
Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A
Anna M. Jankowska et al.
BLOOD (2011)
Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms
Luca Malcovati et al.
BLOOD (2011)
A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q
Pierre Fenaux et al.
BLOOD (2011)
Prevention and treatment of acute myeloid leukemia relapse after allogeneic stem cell transplantation
Betul Oran et al.
CURRENT OPINION IN HEMATOLOGY (2011)
Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome
Matteo G. Della Porta et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Familial myelodysplastic syndromes: a review of the literature
Elena Liew et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Association of Comorbidities With Overall Survival in Myelodysplastic Syndrome: Development of a Prognostic Model
Kiran Naqvi et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Immunosuppressive Therapy for Patients With Myelodysplastic Syndrome: A Prospective Randomized Multicenter Phase III Trial Comparing Antithymocyte Globulin Plus Cyclosporine With Best Supportive Care-SAKK 33/99
Jakob R. Passweg et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Low-Dose Decitabine Versus Best Supportive Care in Elderly Patients With Intermediate-or High-Risk Myelodysplastic Syndrome (MDS) Ineligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group
Michael Luebbert et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Chronic Immune Stimulation Might Act As a Trigger for the Development of Acute Myeloid Leukemia or Myelodysplastic Syndromes
Sigurdur Y. Kristinsson et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
TP53 Mutations in Low-Risk Myelodysplastic Syndromes With del(5q) Predict Disease Progression
Martin Jaedersten et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Somatic SF3B1 Mutation in Myelodysplasia with Ring Sideroblasts
E. Papaemmanuil et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Clinical Effect of Point Mutations in Myelodysplastic Syndromes
Rafael Bejar et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Efficacy of single-agent lenalidomide in patients with JAK2 (V617F) mutated refractory anemia with ring sideroblasts and thrombocytosis
Gerwin Huls et al.
BLOOD (2010)
Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia
Ronan T. Swords et al.
BLOOD (2010)
5-azacitidine prolongs overall survival in patients with myelodysplastic syndrome - a systematic review and meta-analysis
Ronit Gurion et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Myelodysplastic Syndromes Classification and Risk Stratification
Rami S. Komrokji et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2010)
Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM
Christian Rose et al.
LEUKEMIA RESEARCH (2010)
Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2
Myunggon Ko et al.
NATURE (2010)
A phase II study of 5-day intravenous azacitidine in patients with myelodysplastic syndromes
Mike G. Martin et al.
AMERICAN JOURNAL OF HEMATOLOGY (2009)
Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia
Veronique Gelsi-Boyer et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Hematologic Response to Three Alternative Dosing Schedules of Azacitidine in Patients With Myelodysplastic Syndromes
Roger M. Lyons et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Multicenter Study of Decitabine Administered Daily for 5 Days Every 4 Weeks to Adults With Myelodysplastic Syndromes: The Alternative Dosing for Outpatient Treatment (ADOPT) Trial
David P. Steensma et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
Pierre Fenaux et al.
LANCET ONCOLOGY (2009)
Altered naive and memory CD4+T-cell homeostasis and immunosenescence characterize younger patients with myelodysplastic syndrome
J. X. Zou et al.
LEUKEMIA (2009)
Consensus statement on iron overload in myelodysplastic syndromes
John M. Bennett
AMERICAN JOURNAL OF HEMATOLOGY (2008)
Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes
Aristoteles Giagounidis et al.
ANNALS OF HEMATOLOGY (2008)
Erythropoiesis-stimulating agents in the treatment of anemia in myelodysplastic syndromes: a meta-analysis
Victor Moyo et al.
ANNALS OF HEMATOLOGY (2008)
Relationship of Treatment-Related Cytopenias and Response to Lenalidomide in Patients With Lower-Risk Myelodysplastic Syndromes
Mikkael A. Sekeres et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
A prognostic score for patients with lower risk myelodysplastic syndrome
G. Garcia-Manero et al.
LEUKEMIA (2008)
Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes
Luca Malcovati et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Cytogenetic response to lenalidomide is associated with improved survival in patients with chromosome 5q deletion
A. F. List et al.
LEUKEMIA RESEARCH (2007)
Myelodysplastic syndromes - Incidence and survival in the United States
Xiaomei Ma et al.
CANCER (2007)
Prevalence and clinical association of clonal T-cell expansions in Myelodysplastic Syndrome
P. K. Epling-Burnette et al.
LEUKEMIA (2007)
Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia
Hagop Kantarjian et al.
BLOOD (2007)
Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion
Alan List et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: Studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B
Lewis R. Silverman et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Telomerase template antagonist GRN163L disrupts telomere maintenance, tumor growth, and metastasis of breast cancer
Amelia E. Hochreiter et al.
CLINICAL CANCER RESEARCH (2006)
Decitabine improves patient outcomes in myelodysplastic syndromes - Resuits of a Phase III randomized study
H Kantarjian et al.
CANCER (2006)
PRIMA-1 induces apoptosis in acute myeloid leukaemia cells with p53 gene deletion
H Nahi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2006)
Telomerase activity in myelodysplastic syndromes
E Gürkan et al.
LEUKEMIA RESEARCH (2005)
Telomeres and telomerase: their mechanisms of action and the effects of altering their functions
EH Blackburn
FEBS LETTERS (2005)
The myelodysplastic syndromes: Diagnosis, molecular biology and risk assessment
JM Bennett et al.
HEMATOLOGY (2005)
A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes
M Stadler et al.
LEUKEMIA (2004)
A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome
Y Saunthararajah et al.
BLOOD (2003)
Antithymocyte globulin has limited efficacy and substantial toxicity in unselected anemic patients with myelodysplastic syndrome
DP Steensma et al.
BLOOD (2003)
A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin plus granulocyte colony-stimulating factor:: significant effects on quality of life
E Hellström-Lindberg et al.
BRITISH JOURNAL OF HAEMATOLOGY (2003)
A pilot study of antithymocyte globulin (ATG) in the treatment of patients with 'low-risk' myelodysplasia
SB Killick et al.
BRITISH JOURNAL OF HAEMATOLOGY (2003)
Share Paper
